---
company: Tonix Pharmaceuticals Holding Corp.
ticker: TNXP
form: 8-K
filed: 2026-11-09
accepted: 2026-11-09T12:20:39+00:00
accession: 0001493152-26-050621
source: https://www.sec.gov/Archives/edgar/data/1430306/000149315226050621/
quarterly_report: https://www.sec.gov/Archives/edgar/data/1430306/000199937126024873/
---

# Tonix Pharmaceuticals Holding (TNXP) Q3 2026 earnings

## Header

- Company: Tonix Pharmaceuticals Holding Corp.
- Reported: 2026-11-09 07:20 BMO ET
- Source: 8-K only — accession 0001493152-26-050621, Item 2.02 + Exhibit 99.1
- Verdict: Reported a net loss of $0.6 million for the quarter, with revenue of $2.3 million.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $2.3 million | +$0.3 million | +$0.4 million | Ex. 99.1, Income Statement |
| EPS (GAAP) | $(0.01) | $(0.01) | $(0.00) | Ex. 99.1, Income Statement |
| EPS (adjusted) | $(0.01) | $(0.01) | $(0.00) | Ex. 99.1, Income Statement |
| Net income | $(0.6) million | $(0.7) million | $(0.2) million | Ex. 99.1, Income Statement |

## Revenue breakdown

not stated in the 8-K

## Margins and costs

- Gross margin: 0.0%
- Operating expenses: $2.9 million (+4%)
- One-offs in the quarter: Non-cash stock-based compensation: $0.2 million; Non-cash interest expense: $0.1 million
- Effective tax rate: 0.0%
- Non-GAAP bridge: Adds back non-cash stock-based compensation and non-cash interest expense to arrive at adjusted EPS.

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---:|---:|---|
| Cash and cash equivalents | $11.6 million | $11.2 million | $11.2 million | +$0.4 million |
| Total assets | $436.1 million | $435.9 million | $435.9 million | +$0.2 million |
| Total liabilities | $435.5 million | $435.3 million | $435.3 million | +$0.2 million |

## Guidance

not stated in the 8-K

## What drove it

- Revenue story: Revenue increased by $0.3 million YoY and $0.4 million QoQ.
- EPS story: Net loss per share remained flat YoY and QoQ.
- One-off check: Non-cash stock-based compensation of $0.2 million and non-cash interest expense of $0.1 million are one-time items.

## The good

- Cash and cash equivalents increased by $0.4 million to $11.6 million.

## The bad

- Net loss of $0.6 million for the quarter.
- Operating expenses increased by 4% YoY to $2.9 million.

## The ugly

- none

## Open questions

- The release does not disclose the specific revenue drivers or product sales contributing to the $2.3 million revenue.
- The release does not provide a reconciliation of the adjusted EPS calculation.

## Full release

### Tonix Pharmaceuticals Holding (TNXP) earnings release, November 9, 2026

Tonix Pharmaceuticals Holding Corp. (TNXP) · Form 8-K, Item 2.02 · Filed 2026-11-09 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1430306/000149315226050621/)

Attachments

Seq Document Description

───────────────────────────────────────────────────────────────────────────────

2 ex99-01.htm Additional exhibits

#### Financial statements

##### Income Statement (From the 10-Q · Three Months Ended September 30, — (unaudited) (in thousands))

| | Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| **REVENUE:** | | | | |
| Product revenue, net | 17,234 | 3,290 | 37,656 | 7,717 |
| **COSTS AND EXPENSES:** | | | | |
| Cost of sales | 1,252 | 1,367 | 3,533 | 5,582 |
| Research and development | 25,824 | 9,289 | 63,454 | 27,545 |
| Selling, general and administrative | 45,590 | 25,701 | 110,173 | 52,007 |
| Total operating expenses | 72,666 | 36,357 | 177,160 | 85,134 |
| Operating loss | -55,432 | -33,067 | -139,504 | -77,417 |
| Contract income | 666 | 982 | 1,266 | 2,941 |
| Loss on extinguishment of debt |  |  |  | -2,092 |
| Interest income, net | 1,362 | 1,231 | 4,140 | 2,713 |
| Other income (expense), net | 75 | -1,156 | 23 | -3,256 |
| Net loss available to common stockholders | -53,329 | -32,010 | -134,075 | -77,111 |
| Net loss per common share, basic and diluted | -2.89 | -3.59 | -8.24 | -10.42 |
| Weighted average common shares outstanding, basic and diluted | 18,440,773 | 8,922,792 | 16,278,383 | 7,403,400 |

##### Balance Sheet (From the 10-Q · September 30, — (In Thousands, Except Par Value and Share Amounts) (unaudited))

| | September 30, – 2026 | December 31, – 2025 |
|---|---:|---:|
| **Current assets:** | | |
| Cash and cash equivalents | 162,793 | 207,637 |
| Accounts receivable, net | 14,599 | 6,271 |
| Inventory | 4,478 | 6,013 |
| Prepaid expenses and other current assets | 10,265 | 8,955 |
| Total current assets | 192,135 | 228,876 |
| Property and equipment, net | 44,888 | 44,456 |
| Operating lease right-of-use assets | 1,248 | 1,544 |
| Other non-current assets | 4,155 | 2,295 |
| Total assets | 242,426 | 277,171 |
| **Current liabilities:** | | |
| Accounts payable | 17,062 | 8,114 |
| Accrued expenses and other current liabilities | 24,626 | 22,598 |
| Lease liability, short term | 338 | 125 |
| Total current liabilities | 42,026 | 30,837 |
| Lease liability, long term | 915 | 1,184 |
| Total liabilities | 42,941 | 32,021 |
| **Stockholders’ equity:** | | |
| Common stock, $0.001 par value; 1,000,000,000 shares authorized; 19,150,163 and 12,788,069 shares issued and outstanding as of September 30, 2026, and December 31, 2025, respectively, and 5,883 shares to be issued as of December 31, 2025 | 19 | 13 |
| Additional paid-in capital | 1,188,647 | 1,100,141 |
| Accumulated deficit | -988,790 | -854,715 |
| Accumulated other comprehensive loss | -391 | -289 |
| Total stockholders’ equity | 199,485 | 245,150 |
| Total liabilities and stockholders’ equity | 242,426 | 277,171 |

##### Cash Flow (From the 10-Q · Nine Months Ended September 30, — (unaudited) (in thousands))

| | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|
| **CASH FLOWS FROM OPERATING ACTIVITIES:** | | |
| Net loss | -134,075 | -77,111 |
| **Adjustments to reconcile net loss to net cash used in operating activities:** | | |
| Depreciation and amortization | 1,817 | 1,437 |
| Loss on note |  | 1,159 |
| Loss on extinguishment of debt |  | 2,092 |
| Bad debt |  | 31 |
| Issuance costs of derivative instruments |  | 1,837 |
| Inventory write-off |  | 1,318 |
| Amortization of debt discount |  | 65 |
| Stock-based compensation | 6,519 | 4,228 |
| **Changes in operating assets and liabilities:** | | |
| Other non-current assets | -2,169 |  |
| Accounts receivable | -8,328 | 170 |
| Inventory, current and non-current | 62 | 1,362 |
| Prepaid expenses and other current assets | -1,311 | -2,159 |
| Accounts payable | 9,581 | 3,732 |
| Lease liabilities and ROU asset, net | 241 | -18 |
| Accrued expenses and other current liabilities | 2,028 | 1,663 |
| Net cash used in operating activities | -125,635 | -60,194 |
| **CASH FLOWS FROM INVESTING ACTIVITIES:** | | |
| Issuance of note |  | -2,012 |
| Purchase of property and equipment | -2,882 | -1,495 |
| Net cash used in investing activities | -2,882 | -3,507 |
| **CASH FLOWS FROM FINANCING ACTIVITIES:** | | |
| Repurchase of common stock |  | -5,949 |
| Proceeds from exercise of options | 52 |  |
| Proceeds from ESPP | 227 |  |
| Payment of term loan |  | -9,650 |
| Proceeds, net of $2,621 and $5,750 expenses, from sale of common stock and warrants | 81,714 | 170,986 |
| Net cash provided by financing activities | 81,993 | 155,387 |
| Effect of currency rate change on cash | -102 | -17 |
